Evidence map›Paper›PMID 34391981›Full record

ArticleJournal of clinical virology : the official publication of the Pan American Society for Clinical Virology2021

Adaptive immune responses to SARS-CoV-2 in recovered severe COVID-19 patients.

Beatriz Olea, Eliseo Albert, Ignacio Torres, Paula Amat, María José Remigia, Roberto Gozalbo-Rovira, Jesús Rodríguez-Díaz, Javier Buesa, María Luisa Blasco, Josep Redón and 2 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
0.7field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Association of trace element status in COVID-19 patients with disease severity.Journal of trace elements in medicine and biology : organ of the Society for Minerals and Trace Elements (GMS) · 2022
    Article
  4. Long-Term, CD4Frontiers in immunology · 2022
    Article
  5. TheFrontiers in genetics · 2022
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Beatriz OleaMicrobiology Service, Clinic University Hospital, INCLIVA Health Research Institute, Valencia, Spain.
Eliseo AlbertMicrobiology Service, Clinic University Hospital, INCLIVA Health Research Institute, Valencia, Spain.
Ignacio TorresMicrobiology Service, Clinic University Hospital, INCLIVA Health Research Institute, Valencia, Spain.
Paula AmatHematology Service, Clinic University Hospital, INCLIVA Health Research Institute, Valencia, Spain.
María José RemigiaHematology Service, Clinic University Hospital, INCLIVA Health Research Institute, Valencia, Spain.
Roberto Gozalbo-RoviraDepartment of Microbiology, School of Medicine, University of Valencia, Valencia, Spain.
Jesús Rodríguez-DíazMedical Intensive Care Unit, Clinic University Hospital, INCLIVA Health Research Institute, Valencia, Spain.
Javier BuesaMicrobiology Service, Clinic University Hospital, INCLIVA Health Research Institute, Valencia, Spain; Department of Microbiology, School of Medicine, University of Valencia, Valencia, Spain.
María Luisa BlascoMedical Intensive Care Unit, Clinic University Hospital, INCLIVA Health Research Institute, Valencia, Spain.
Josep RedónInternal Medicine Department, Clinic University Hospital, INCLIVA Health Research Institute, Valencia, Spain; Department of Medicine, School of Medicine, University of Valencia, Valencia, Spain.
Jaime Signes-CostaPneumology Service, Clinic University Hospital, INCLIVA Health Research Institute, Valencia, Spain.
David NavarroMicrobiology Service, Clinic University Hospital, INCLIVA Health Research Institute, Valencia, Spain; Department of Microbiology, School of Medicine, University of Valencia, Valencia, Spain. Electronic address: david.navarro@uv.es.
INCLIVA Health Research Institute · ESUniversitat de València · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThere is an imperative need to determine the durability of adaptive immunity to SARS-CoV-2. We enumerated SARS-CoV-2-reactive CD4 PATIENTS AND

methodsWe recruited 58 patients (38 males and 20 females; median age, 62.5 years), who had been hospitalized with bilateral pneumonia, 60% with one or more comorbidities. IgG antibodies binding to SARS-CoV-2 RBD were measured by ELISA. SARS-CoV-2-reactive CD69

resultsDetectable SARS-CoV-2-S1/M-reactive CD69

conclusionA relatively limited number of subjects who developed severe forms of COVID-19 had detectable SARS-CoV-2-S1/M IFNγ CD4

Indexed as

COVID-19SARS-CoV-2Antibodies, ViralCD8-Positive T-LymphocytesFemaleHumansImmunityMaleMiddle AgedAntibodies, ViralCOVID-19Receptor binding domain-specific IgG antibodiesSARS-CoV-2T cells

Identifiers

PMID34391981
PMCPMC8349475
OpenAlexW3191895439

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.